Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. (Nasdaq: TKNO) is a producer of critical reagents for the life sciences industry, with news flow that reflects its role in supporting therapies, vaccines, molecular diagnostics, and cell therapies. Company updates often highlight performance across its Lab Essentials and Clinical Solutions product groupings, as well as developments in its manufacturing platform and collaborations.
Investors and observers following TKNO news can expect regular earnings announcements and related commentary on revenue trends, gross margin, operating expenses, and non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow. These updates are typically furnished through press releases and accompanying Form 8-K filings that discuss quarterly and full-year financial results and provide revenue breakdowns by Lab Essentials, Clinical Solutions, and Other categories.
Teknova’s news also includes product and partnership announcements. A notable example is its collaboration with Pluristyx, Inc. on the PluriFreeze cryopreservation system, where Teknova serves as the exclusive manufacturer and distributor in the United States and Canada. Press releases describe how this system is intended to streamline the manufacture of next-generation allogeneic cell therapies through synthetic, animal-origin-free cryopreservation and wash media.
Additional news items cover guidance for upcoming periods, descriptions of the company’s participation in investor conferences, and reminders about scheduled earnings calls and webcasts. For readers interested in how a life science reagents supplier communicates its financial performance, product evolution, and strategic collaborations, the TKNO news feed provides an ongoing record of Teknova’s public disclosures and corporate milestones.
Teknova (TKNO) reported its Q4 and full-year 2024 financial results, with total revenue reaching $37.7 million for FY2024, up 3% year-over-year. Q4 2024 revenue was $9.3 million, an 18% increase from Q4 2023.
Key highlights include:
- Clinical Solutions revenue grew 110% in Q4 2024 to $1.9 million
- 41% annual growth in Clinical Solutions customers
- Lab Essentials revenue reached $6.8 million in Q4, up 2%
- Year-end cash position of $30.4 million with $12.1 million in gross debt
The company improved its operational efficiency and reduced cash burn, with free cash outflow decreasing to $13.5 million in 2024 from $26.7 million in 2023. For 2025, Teknova provided revenue guidance of $39-42 million with expected free cash outflow below $12 million.
Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, after market close. The company will host a webcast and conference call at 5 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants requiring dial-in information need to register to receive a unique PIN number.
Teknova (TKNO) reported Q3 2024 revenue of $9.6 million, up 17% year-over-year. The company reaffirmed its 2024 revenue guidance of $35-38 million while lowering its free cash outflow outlook from $18 million to $16 million. Q3 Lab Essentials revenue remained stable at $7.2 million, while Clinical Solutions revenue grew 229% to $2.0 million. The company recorded a $2.8 million non-recurring charge related to inventory write-downs, resulting in a gross margin of 0.9%. Excluding this charge, gross margin would have been 29.8%. Total cash and short-term investments stood at $31.7 million with gross debt of $12.1 million.
Alpha Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has announced it will release its third quarter 2024 financial results on November 7, 2024, after market close. The company will host a webcast and conference call at 5:30 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants need to register to receive dial-in information.
Teknova (NASDAQ: TKNO) reported Q2 2024 financial results, with total revenue of $9.6 million, up 3% sequentially but down 17% year-over-year. The company reaffirmed its 2024 revenue guidance of $35-38 million. Key highlights include:
- Raised $15.4 million in equity capital in July 2024
- Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade
- Clinical customers increased by 26% to 43 in the past six months
- Q2 2024 gross profit was $2.8 million with a 29.2% gross margin
- Net loss for Q2 2024 was $5.4 million, or -$0.13 per diluted share
- Free Cash Flow was -$3.0 million for Q2 2024
The company remains cautiously optimistic about market recovery and maintains its full-year outlook.
Teknova (NASDAQ: TKNO) has launched two new offerings to enhance product customization and expedite novel therapy development:
- Express-Tek℠ Production: A proprietary service that reduces custom product turnaround time by an average of two weeks, allowing products to enter production in days instead of weeks.
- RUO+ Manufacturing Grade: A new grade bridging the gap between research and clinical-grade production, providing a seamless and cost-effective option for scaling from discovery to clinical manufacturing.
These offerings aim to accelerate therapeutic development by providing faster manufacturing, delivery of critical reagents, and flexible scaling options for customers transitioning from research to clinical trials.
Alpha Teknova (Nasdaq: TKNO), a leading producer of critical reagents for novel therapies, vaccines, and molecular diagnostics, has announced its plans to report second quarter 2024 financial results on August 13, 2024, after market close. The company will host a webcast and conference call on the same day at 5:00 p.m. Eastern Time to discuss the results.
Investors and interested parties can access the live webcast through the Investor Relations section of Teknova's website or via a provided link. To participate in the call, registration is required to receive a unique PIN and dial-in information. A replay of the webcast will be available on the company's website approximately two hours after the event concludes.
Alpha Teknova has closed a $15.4 million private placement involving the issuance of 12,385,883 shares at $1.24 each, based on the Nasdaq closing price on July 11, 2024.
The gross proceeds from this private placement are approximately $15.4 million, before expenses. The funds will be used for general corporate purposes.
The securities from this transaction are not registered under the Securities Act and can only be resold under specific conditions. This announcement does not constitute an offer to sell or buy these securities in jurisdictions where such actions are unlawful.
Teknova (Nasdaq: TKNO) announced a $15.4 million private placement of 12,385,883 shares of common stock at $1.24 per share, based on the Nasdaq Official Closing Price on July 11, 2024. The private placement is set to close around July 12, 2024, contingent on standard closing conditions. Gross proceeds will be approximately $15.4 million before expenses, and the net proceeds will be used for general corporate purposes. This private placement is not registered under the Securities Act of 1933 but will comply with SEC regulations for resale. Teknova plans to file a registration statement with the SEC within 45 days and aims for it to be effective within 120 days if reviewed by the SEC.
Alpha Teknova (Nasdaq: TKNO) has provided a strategic business update and preliminary financial results for Q2 2024. The company anticipates total revenue between $9.4 to $9.6 million, reflecting a 17% to 18% decline compared to Q2 2023. However, excluding a large order from Q2 2023, the revenue shows a 7% to 9% increase. Teknova reaffirms its fiscal 2024 revenue guidance of $35-38 million and expects free cash outflow to be less than $18 million for the year. Cost management has led to a 40% reduction in headcount since Q2 2022. Key highlights include growth in the number of Clinical Solutions customers from 34 to 43 and an increase in Lab Essentials customers from 2,829 to 2,913, with on-time delivery metrics at an all-time high. Full financial results will be released on August 13, 2024.